论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Denis D, Beneton N, Laribi K, Maillard H
Received 19 August 2018
Accepted for publication 20 December 2018
Published 20 March 2019 Volume 2019:11 Pages 2241—2251
DOI https://doi.org/10.2147/CMAR.S138661
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Abstract: Mycosis fungoides (MF) is a low-grade
cutaneous lymphoma accounting for more than half of primary cutaneous T-cell
lymphomas (CTCLs). Due to the rarity of CTCL, randomized studies are lacking,
and treatment is based mainly on the recent published European Organisation for
Research and Treatment of Cancer guidelines. Basically, early-stage MF is
treated with skin-directed treatments, whereas advanced-stage MF requires more
aggressive therapies. Among the skin-directed therapies, nitrogen mustard has
been used for more than 50 years. A gel formulation was developed recently,
showing a slight decrease in efficacy, counterbalanced by better tolerance
(essentially due to a decrease in delayed hypersensitivity reactions). This
review aims to summarize the current management of MF and the role of
chlormethine gel in the treatment of the disease.
Keywords: mycosis
fungoides, nitrogen mustard, mechlorethamine, chlormethine, gel
摘要视频链接:Chlormethine gel on
MF